FY2024 Earnings Forecast for Kamada Issued By HC Wainwright

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Kamada in a report released on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $0.25 per share for the year, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.24 per share.

Separately, StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Trading Down 0.9 %

NASDAQ:KMDA opened at $5.81 on Monday. The firm’s 50 day moving average is $5.48 and its 200 day moving average is $5.47. Kamada has a 12 month low of $4.60 and a 12 month high of $6.53. The stock has a market capitalization of $333.96 million, a PE ratio of 20.75 and a beta of 1.05.

Institutional Trading of Kamada

Institutional investors have recently modified their holdings of the business. Y.D. More Investments Ltd grew its stake in Kamada by 1,956.0% in the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after buying an additional 690,842 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Kamada in the third quarter valued at $117,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Kamada during the 3rd quarter valued at $77,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.